How to Cite
Abstract
The aim of the study: to evaluate efficacy and toxicity of interstitial high-dose-rate prostate brachytherapy when it was used as monotherapy for low-, intermediate risk prostate cancer.
Material and methods: 198 primary patients with low-, intermediate risk prostate cancer that were treated from 1.07.2012 to 01.07.2017 were included in the study. Two fractions of 13Gy were used in 67 men, 3 fractions of 11.5Gy -in the remaining 131 patients. The reported end points were overall/cancer-specific survival, biochemical control rates according to Phoenix definition. Toxicity was scored according to the RTOG scale.
Results: The median follow-up time was 28.7 [19.3; 36.6] (10.9-58.9) months. The 3-year biochemical control (nadir+2) was reached in 94.1% cases. Late grade III genito-urinary toxicity was represented by urethral strictures in 1.6% of evaluated patients. Grade III rectal toxicity was not mentioned. IIEF score before treatment was below 16 in 28.8% patients and after brachytherapy - in 52.9% cases.
Conclusion: high dose rate brachytherapy can be effectively and safely used for monotherapy of patients with low-, intermediate risk prostate cancer.
References
Канаев С.В., Новиков С.Н. Особенности высокодозной брахитерапии больных локализованным раком предстательной железы // Вопросы онкологии. - 2013. - Т. 59(5). - С. 645-650.
Кызласов П.С., Сокольщик М.М., Байкова Н.В. и др. Недержание мочи после радикальной простатэктомии // Экспериментальная и клиническая урология. - 2015. - №3. - С. 38-41.
Новиков С.Н., Канаев С.В., Новиков Р.В. и др. Высокодозная брахитерапия рака предстательной железы в режиме реального времени с использованием источника 192-Ir (особенности дозиметрического планирования) // Вопросы онкологии. - 2015. - Т. 61. - № I. - С. 130-136.
Новиков С.Н., Канаев С.В., Баянкин С.Н. и др. рекомендации по лечению рака предстательной железы с помощью высокомощностной внутритканевой лучевой терапии (брахитерапии) Экспертное совещание, 17 ноября 2016, Москва // Экспериментальная и клиническая урология. - 2017. - № 3. - С. 10-23.
Харченко В.П., Каприн А.Д., Паньшин Г.А. и др. Высокодозная брахитерапия рака предстательной железы - технология будущего // Вопросы онкологии. - 2008. - Т. 54(6). - С. 765-767.
Barocas D.A., Alvarez J., Resnick M.J. et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years // J.A.M.A. - 2017. - Vol. 317. - № II. - P 1126-1140.
Benoit R.M., Naslund M.J., Cohen J.K. Complications after radical retropubic prostatectomy in the medicare population // Urology. - 2000. - Vol. 56(1). - P 116-120.
Chen R.C., Basak R., Meyer A.M. et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer // J.A.M.A. - 2017. - Vol. 317. - № 11. - P. 1141-1150.
de Bari B., Daidone A., Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature // Crit. Rev. Oncol. Hematol. -2015. - Vol. 94. - № 3. - P 360-370.
Fajardo L.F. The pathology of ionizing radiation as defined by morphologic patterns // Acta. Oncol. - 2005. - Vol. 44. - № 1. - Р. 13-22.
Hamdy F.C., Donovan J.L., Lane J.A. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer // N. Engl. J. Med. - 2016. - Vol. 375. - № 15. - Р 1415-1424.
Hauswald H., Kamrava M.R., Fallon J.M. et al. High-doserate monotherapy for localized prostate cancer: 10-year results // Int. J. Radiat. Oncol. Biol. Phys. - 2016. - Vol. 94. - № 4. - P. 667-674.
Heesakkers J., Farag F., Bauer R.M. et al. Pathophysiology and contributing factors in postprostatectomy incontinence: a review // Eur. Urol. 2017. Vol. 71, № 6. Р 936-944.
Herschorn S., Elliott S., Coburn М. et al. SIU/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer// Urology. - 2014. - Vol. 83, suppl. 3. - P. 59-70.
Jazayeri S.B., Weissman B., Samadi D.B. Outcomes following robotic-assisted laparoscopic prostatectomy: Pentafecta and Trifecta achievements// Minerva Urol. Nefrol. - 2018. - Vol. 70. - № 1. - Р 66-73.
Jawad M.S., Dilworth J.T., Gustafson G.S. et al. Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. - 2016. - Vol. 94 - № 4. - P. 657-666.
Incrocci L. Radiotherapy for prostate cancer and sexual health // Transl. Androl. Urol. -2015. - Vol. 4. - № 2. - Р 124-130.
Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent // Eur. Urol. - 2017. - Vol. 71. - № 4. - Р 618-629.
Mohammed N., Kestin L., Ghilezan M.et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. - 2012. - Vol. 82. - № 1. - Р 204-212.
Roach M. 3rd. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference / M. 3rd Roach, G. Hanks, H. Jr. Thames et al. // Int. J. Radiat. Oncol. Biol. Phys. - 2006. - Vol. 65. - № 4. - Р 965-974.
Salomon L., Droupy S., Yiou R., Soulié M. The long-term effect of radical prostatectomy on erectile function, urinary continence, and lower urinary tract symptoms: a comparison to age-matched healthy controls // Biomed. Res. Int. - 2017. - DOI: 10.1155/2017/9615080
Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and manage ment of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery // Eur. Urol. - 2012. - Vol. 62(2). - P 261272. - DOI: 10.1016/j.eururo.2012.04.046
Stember D.S., Mulhall J.P The concept of erectile function preservation (penile rehabilitation) in the patient after Brachytherapy for prostate cancer // Brachytherapy. - 2012. - Vol. 11. - № 2. - Р 87-96.
Tselis N., Hoskin P, Baltas D. et al. High dose rate brachytherapy as monotherapy for localised prostate cancer: review of the current status // Clin. Oncol. (R Coll Radiol). - 2017. - DOI: 10.1016/j.clon.2017.02.015
Yang R., Zhao N., Liao A. et al. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer // Med. Dosim. - 2016. - Vol. 41. - № 3. - Р 236-241.
Yoshida K. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate // Anticancer Res. - 2014. - Vol. 34. - № 4. - P. 2015-2018.
Yoshioka Y, Nose T, Yoshida K. et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 48. - № 3. - Р 675-681.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018